دورية أكاديمية
أعرض في EDS

Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.

التفاصيل البيبلوغرافية
العنوان: Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
المؤلفون: Tekle AH; African Programme for Onchocerciasis Control, WHO/APOC P, O, Box: 01 B,P, 549, Ouagadougou 01, Burkina Faso. afeworkh@oncho.afro.who.int, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, Cousens S, Abiose A, Remme JH
المصدر: Parasites & vectors [Parasit Vectors] 2012 Feb 07; Vol. 5, pp. 28. Date of Electronic Publication: 2012 Feb 07.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101462774 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-3305 (Electronic) Linking ISSN: 17563305 NLM ISO Abbreviation: Parasit Vectors Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central
مواضيع طبية MeSH: Antiparasitic Agents/*therapeutic use , Ivermectin/*therapeutic use , Onchocerca volvulus/*drug effects , Onchocerciasis/*drug therapy, Adolescent ; Adult ; Animals ; Child ; Child, Preschool ; Disease Eradication ; Female ; Humans ; Infant ; Male ; Middle Aged ; Nigeria/epidemiology ; Onchocerciasis/epidemiology ; Onchocerciasis/prevention & control ; Prevalence ; Public Health ; Young Adult
مستخلص: Background: Onchocerciasis can be effectively controlled as a public health problem by annual mass drug administration of ivermectin, but it was not known if ivermectin treatment in the long term would be able to achieve elimination of onchocerciasis infection and interruption of transmission in endemic areas in Africa. A recent study in Mali and Senegal has provided the first evidence of elimination after 15-17 years of treatment. Following this finding, the African Programme for Onchocerciasis Control (APOC) has started a systematic evaluation of the long-term impact of ivermectin treatment projects and the feasibility of elimination in APOC supported countries. This paper reports the first results for two onchocerciasis foci in Kaduna, Nigeria.
Methods: In 2008, an epidemiological evaluation using skin snip parasitological diagnostic method was carried out in two onchocerciasis foci, in Birnin Gwari Local Government Area (LGA), and in the Kauru and Lere LGAs of Kaduna State, Nigeria. The survey was undertaken in 26 villages and examined 3,703 people above the age of one year. The result was compared with the baseline survey undertaken in 1987.
Results: The communities had received 15 to 17 years of ivermectin treatment with more than 75% reported coverage. For each surveyed community, comparable baseline data were available. Before treatment, the community prevalence of O. volvulus microfilaria in the skin ranged from 23.1% to 84.9%, with a median prevalence of 52.0%. After 15 to 17 years of treatment, the prevalence had fallen to 0% in all communities and all 3,703 examined individuals were skin snip negative.
Conclusions: The results of the surveys confirm the finding in Senegal and Mali that ivermectin treatment alone can eliminate onchocerciasis infection and probably disease transmission in endemic foci in Africa. It is the first of such evidence for the APOC operational area.
References: World Health Organ Tech Rep Ser. 1995;852:1-104. (PMID: 7541171)
Filaria J. 2003 Feb 7;2(1):2. (PMID: 12605722)
Bull World Health Organ. 1986;64(5):667-81. (PMID: 3492300)
World Health Organ Tech Rep Ser. 1987;752:1-167. (PMID: 3120423)
Bull World Health Organ. 1997;75(3):229-36. (PMID: 9277010)
J Infect Dis. 2001 Aug 15;184(4):497-503. (PMID: 11471108)
Trop Med Int Health. 2004 Feb;9(2):243-54. (PMID: 15040562)
Lancet. 1993 Jan 16;341(8838):130-4. (PMID: 8093742)
Med Trop (Mars). 1978 Sep-Oct;38(5):519-32. (PMID: 745526)
Bull World Health Organ. 2002;80(5):384-91. (PMID: 12077614)
Parasitology. 2005 Apr;130(Pt 4):447-53. (PMID: 15830819)
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:7-11. (PMID: 18718147)
Ann Trop Med Parasitol. 2006 Dec;100(8):733-46. (PMID: 17227651)
PLoS Negl Trop Dis. 2009 Jul 21;3(7):e497. (PMID: 19621091)
Br J Ophthalmol. 1994 Jan;78(1):8-13. (PMID: 8110711)
Lancet. 1991 Jun 1;337(8753):1358-9. (PMID: 1674345)
Bull World Health Organ. 1989;67(6):707-19. (PMID: 2633886)
Int J Parasitol. 2011 Apr;41(5):581-9. (PMID: 21255577)
Lancet Infect Dis. 2008 May;8(5):310-22. (PMID: 18471776)
Parasit Vectors. 2011 Oct 25;4:205. (PMID: 22024050)
Parasit Vectors. 2011 Jul 27;4:152. (PMID: 21794139)
Acta Trop. 1991 Feb;48(4):271-84. (PMID: 1674401)
Am J Trop Med Hyg. 2004 Nov;71(5):602-7. (PMID: 15569792)
Trop Med Int Health. 2004 Aug;9(8):882-6. (PMID: 15303993)
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:19-22. (PMID: 18718149)
المشرفين على المادة: 0 (Antiparasitic Agents)
70288-86-7 (Ivermectin)
تواريخ الأحداث: Date Created: 20120209 Date Completed: 20140701 Latest Revision: 20220409
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC3296569
DOI: 10.1186/1756-3305-5-28
PMID: 22313631
قاعدة البيانات: MEDLINE
الوصف
تدمد:1756-3305
DOI:10.1186/1756-3305-5-28